Introduction {#s1}
============

Lung cancer is the most common malignancy in the world and the leading cancer in males, accounting for 17% of the total new cancer cases and 23% of the total cancer deaths [@pone.0102372-Tyczynski1]--[@pone.0102372-Zhao1]. The burden of lung cancer mortality in females in developing countries is up to 11% of the total female cancer deaths [@pone.0102372-Jemal1]. In the United States, there were 226,160 newly diagnosed cases and 160,340 deaths due to lung cancer in 2012 [@pone.0102372-Siegel1]. In China, although females have a lower prevalence of smoking, there is still higher lung cancer rates (21.3 cases per 100,000 females) than those in European countries [@pone.0102372-Lam1], due to indoor air pollution, cooking fumes, occupational and environmental pollutions. Besides, due to the incurable nature and less than a five-year survival rate (only 16%), lung cancer has attracted a huge attention across the whole world [@pone.0102372-American1].

Lung cancer can be divided into several types by pathological classification, such as squamous cell carcinoma (SC), adenocarcinoma (AC) and large or small cell carcinoma. It is also classified as small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), which accounts for about 85% of all lung cancer [@pone.0102372-Paez1]. Given the possible relapses in the local respiratory system and the metastasis in other systems after the classical treatments of radical surgery, immunotherapy has provided an innovative method for lung cancer treatment in the past 30 years to enhance the clinical outcome, alleviate the disease burden, prevent recurrences and attenuate toxicity [@pone.0102372-Ramalingam1]--[@pone.0102372-Shi1].

Tobacco smoking has clearly been demonstrated to be a strong exogenous factor for lung cancer risk [@pone.0102372-Wingo1]--[@pone.0102372-Hecht1]. Polycyclic aromatic hydro-carbons (PAHs) and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) are considered to be the major carcinogens, which can interact with DNA and cause the formation of DNA adducts [@pone.0102372-Hecht1]. In the meantime, free radicals from tobacco smoking can induce oxidative damage to lung tissues, and also damage DNA, which provides another clue to lung cancer development [@pone.0102372-Loft1]--[@pone.0102372-Gackowski1]. In this process, DNA was damaged by superoxide anions (O~2~ ^−^) and hydroxyl radicals (OH^−^) and was repaired by antioxidant enzymes. This balance can be broken by both environmental and genetic factors. Available molecular epidemiology studies have shown that genetic polymorphisms play a major role in the progress of carcinoma [@pone.0102372-Liu1], [@pone.0102372-deMello1]. Among these studies, genetic variants of carcinogen-metabolizing enzymes have received much attention, especially glutathione S-transferase (GST) genes and cytochrome P450 genes. The cytochrome P450 (CYP450) family, as the first-pass metabolism enzymes, plays an important role in many physiological and biochemical reactions in the human body, and participates in the metabolic process of endogenous and exogenous substrates (biosynthesis and degradation) [@pone.0102372-Hu1]. Toxic materials like benzo\[a\]-pyrene and other PAHs could be metabolized to oxygenated intermediates and then degraded sequentially to lower toxic or non-toxic substances by the second-pass metabolic enzymes such as the glutathione S-transferases (GSTs) family [@pone.0102372-Nebert1], [@pone.0102372-Smith1]. Therefore, the polymorphisms of both gene families might affect the metabolism of tobacco toxicants in lung and finally influence the advancement of cancer.

The GSTs family can detoxify environmental carcinogens and toxins, oxidative stress products, and several covalent conjugated electrophilic compounds [@pone.0102372-Udomsinprasert1], [@pone.0102372-Frova1]. *GSTM1* and *GSTT1* are two critical GSTs family genes, separately encoded mu and theta GST classes and located in 1p13.3 and 22q11.23 in the human chromosome, respectively. The common *GSTM1* polymorphisms include three alleles, *GSTM1\*A*, *GSTM1\*B* and *GSTM1\*0*, where *GSTM1\*0* means a null mutation [@pone.0102372-Fryer1]. Another gene, *GSTT1* is polymorphic with two alleles (*GSTT1\*1* and *GSTT1\*0*). The homozygous combinations of *GSTM1\*0* allele as a null genotype could lead to a functional deficiency [@pone.0102372-Fryer1], as well as *GSTT1\*0* [@pone.0102372-Pemble1], while other genotypes remain functional [@pone.0102372-Dejong1]--[@pone.0102372-Bolt1].

Most molecular epidemiologic studies suggested an association between GST genetic polymorphisms and lung cancer risk, especially when deletion of *GSTM1* is observed in the Asian population [@pone.0102372-Ye1]--[@pone.0102372-Vlastos1]. However, the current research results are conflicting, especially in the Chinese population [@pone.0102372-Shukla1], [@pone.0102372-Li2], [@pone.0102372-Lee1], [@pone.0102372-Vlastos1]--[@pone.0102372-Hosgood1]. Due to the difference in sample size, smoking status and environmental factors, etc., conflicting or vague results were found in these studies.

To identify the association of two vital GST genetic polymorphisms (*GSTM1* and *GSTT1*) with lung cancer risk, an updated systematic meta-analysis was performed in this study by selecting all eligible studies in the Chinese population.

Methods {#s2}
=======

1. Literature research strategy {#s2a}
-------------------------------

A computer-based literature search was carried out in EMBASE, PubMed, ISI Web of Knowledge, Chinese Biomedical Database (CBM), VIP database, Chinese National Knowledge Infrastructure (CNKI), and Wanfang Data (the latest research retrospect until October 2013) to collect articles related to the association of *GSTM1* and/or *GSTT1* polymorphisms and lung cancer susceptibility in the Chinese population. Additionally, relevant references of the articles were also collected. We also searched two websites (<http://www.baidu.com> and <http://scholar.google.com>) to identify additional eligible studies. MeSH terms ("glutathione S-transferase" or "GST" or "GSTM1" or "GSTT1") and ("lung carcinoma" or "lung cancer" or "lung neoplasms") and ("China" or "Chinese" or "Taiwan") were used in the databases. Eligible research articles not captured by the above research strategies were further searched by bibliographies without language limitation.

2. Inclusion and exclusion criteria {#s2b}
-----------------------------------

Inclusion criteria: (1) individuals or samples in all eligible studies were examined and diagnosed by polymerase chain reaction (PCR), pathologic diagnosis or other methods to get a full picture of GST genetic polymorphisms and lung cancer types; (2) Chinese living in China; (3) articles providing raw data including odds ratio (OR) with 95% confidence interval (CI) and respective variance, or the relevant information could be calculated.

Exclusion criteria: (1) Chinese out of China; (2) raw data not available; (3) when there were multiple publications by the same researchers, only the latest or the largest population study was adopted; (4) meeting abstract, case reports, editorials, newsletter and review articles were excluded.

3. Data extraction and synthesis {#s2c}
--------------------------------

To decide inclusively or exclusively, articles were identified by three independent work groups (group 1-Kui Liu and Lu Zhang; group 2-Xia Yue and Xialu Lin; group 3-Jian Chen and Guixiu Jin) using a standardized data extraction form designed by ourselves. Discrepancies among three groups were further discussed by all parties. If consenses was still not reached, another group (group 4-Huiqin Wang and Qi Zhou) would make the final decision. Firstly, the titles and abstracts of all studied articles were screened to determine their relevance. If the titles and abstracts were ambiguous, full articles would be investigated. In order to make full use of the available data, it was counted as two separated studies if two different control groups were employed in the same article, such as two different controls versus the same control. If there were more than one region to be investigated in one article, information for each region was also counted as a separated study. Information collected from each eligible study included: first author, year of publication, region, study time, pathologic diagnosis, source of control, characteristics of cases and controls, genotype frequency of null *GSTM1*, null *GSTT1*, and null of both genotypes ([Table 1](#pone-0102372-t001){ref-type="table"}). Hardy Weinberg Equilibrium(HWE) argues that genotype frequencies at any locus are a simple function of allele frequencies under the precondition of no migration, mutation, natural selection, and assortative mating [@pone.0102372-Hardy1]. HWE test was usually assessed in the control group [@pone.0102372-Schaid1]. Furthermore, details of eligible studies used for detecting GSTs genotype, combined evaluation of other genes, HWE test results of *CYP1A1* polymorphisms, the percent of null GSTs genotype in the control groups, smoking status, study type and quality score were also elicited ([Table 2](#pone-0102372-t002){ref-type="table"}). Study types also consisted of epidemiological design and non-epidemiological design. Epidemiological designs were comprised of case-control, cohort and nested case-control studies, all of which must satisfy three conditions for both cases and controls: explicit diagnosis of status (histology or cytology), clear description of the age period, and the same source population [@pone.0102372-Klug1]. Those not meeting the conditions were considered non-epidemiological designs. The quality score of epidemiological studies was evaluated by Newcastle-Ottawa Scale (NOS).

10.1371/journal.pone.0102372.t001

###### Characteristics of the studies related to the effects of GSTs genetic polymorphisms and lung cancer risk.

![](pone.0102372.t001){#pone-0102372-t001-1}

  No.                    First author(ref.)                              Region                  Study time      Pathologic diagnosis^¶^      Sourceof controls                                    Characteristic of Cases                                                                                  Characteristic of Controls                                                          Null *GSTM1*/Group number                Null *GSTT1*/Group number                 Dual Null/Group number                                                           
  ------- ------------------------------------------------- --------------------------------- ----------------- ------------------------- ------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ---------------------------------------- --------------------------------------- --------------------------------------- -------- ---------
  1\*             Liu DZ 2012 [@pone.0102372-Liu2]                Heilongjiang (Harbin)          2010--2012                ALL                   Population                    360 cases in Han population (142 SC, 140 AC, 37 SCLC, 41 others)                                        360 cancer-free controls matched by gender and age in Han population                                              145/360                                  107/360                                                                                                           
  2               Wang N 2012 [@pone.0102372-Wang2]                       Henan                2008.2--2008.8              ALL                   Population                              209cases(103 SC, 69 AC, 28 SCLC and 9 others                                                      256 controls, comparable in age and gender in Han population                                                  122/209                                  113/256                                  90/209                                  100/256                          
  3\*              Li WY 2012 [@pone.0102372-Li3]                        Beijing               2005.8--2006.6              ALL                   Population                                           217 cases (NSCLC)                                                                       198 healthy controls with comparable in age and gender                                                     127/217                                   93/198                                                                                                           
  4              Chen CM 2012 [@pone.0102372-Chen1]                     Zhejiang                     NA                    ALL                   Population                                200 cases (59 AC, 104SC, 37 other NSCLC)                                                      200 controls without any tumor with comparable in gender and age                                                123/200                                  110/199                                                                                                           
  5               Yao ZG 2012 [@pone.0102372-Yao1]                       Beijing               2006.6--2010.6              ALL                   Population                              150 cases including 97 males and 53 females                                                          150 healthy controls including 89 males and 61 females                                                      96/150                                   68/150                                                                                                           
  6               Liu JN 2012 [@pone.0102372-Liu3]                         NA                        NA                    NA                    Population                      100 cases including 29 SC, 40 AC, 18SCLC and 13 mixed style                                 135 healthy controls with comparable in gender, age and smoking status in Han population                                                                                                                      57/100                                  56/135                           
  7               Han RL 2012 [@pone.0102372-Han1]                    InnerMongolia                  NA                    ALL                    Hospital                                                128 cases                                                                214 hospital controls without tumors, rheumaticdisease and pulmonary disease                                           79/128                                   89/214                                                                                                           
  8\*              Jin YT 2011[@pone.0102372-Jin1]                        Anhui                  2006--2007                ALL                    Hospital                                            154 cases (NSCLC)                                               154 controls without any tumors and chronic respiratory disease, matched by age, gender and ethnicity.                              64/154                                   58/154                                                                                                           
  9                 Ai C 2011 [@pone.0102372-Ai1]                          NA                  2007.5--2010.5              ALL                   Population                                          50 cases (38 males)                                                   50 controls with comparable in gender, age, ethnicity, smoking status and occupational group                                   36/50                                    23/50                                                                                                            
  10            Zhang JQ 2011 [@pone.0102372-Zhang1]                Yunnan (Xuanwei)                 NA                    ALL                   Population                                                50 cases                                                     50 controls, comparable in gender, age, residential township, weight and combustion method of coal                                34/50                                    22/50                                                                                                            
  11               Du GB 2011 [@pone.0102372-Du1]                        Sichuan                     NA                    ALL                    Hospital                                   125 cases (57 SC, 31 AC, 37 others)                                                                  125 controls with comparable in age and gender                                                          73/125                                   71/125                                                                                                           
  12                Li Y2011 [@pone.0102372-Li4]                    Henan (Zhengzhou)            2003--2006                ALL                   Population                          103 cases including 64 SC, 13 AC,21SCLC and 5 others                                                       138 healthy controls, comparable in age and gender                                                        63/103                                   61/138                                                                                                           
  13               Bai TY 2011[@pone.0102372-Bai1]                    InnerMongolia              2006--2009                ALL                    Hospital                                                106 cases                                                                     250 controls without tumors, rheumaticdisease and pulmonary disease                                                                                                                                50/106                                  111/250                          
  14\*             Jin YT 2010[@pone.0102372-Jin2]                        Anhui                2005.6--2007.12             ALL                    Hospital                                 150 cases (83 SC, 33AC, 34 mixed types)                                                                    150 controls matched by age and gender.                                                             95/150                                   79/150                                                                                                           
  15             Zheng DJ 2010[@pone.0102372-Zheng1]                     Tianjin               2008.3--2009.7              ALL                   Population                        265 cases including 120 SC, 99AC, 23 SCLC and 23 others                       307 healthy controls without respiratory disease and family history of lung cancer, comparable in age and gender                        150/265                                  175/307                                                                                                           
  16               Zhu XX 2010[@pone.0102372-Zhu1]                        Hunan                2009.3--2009.12             ALL                   Population                           160 female cases (19SC, 109AC, 17SCLC, 15 others)                                               160 healthy female controls, comparable in age and residential township                                             93/160                                   72/160                                                                                                           
  17               Fan J 2010 [@pone.0102372-Fan1]                       Guangxi               2009.3--2010.5              ALL                   Population                                                58 cases                                                                       60 healthy controls, comparable in age and residential township                                                 40/58                                    33/60                                    38/58                                   29/60                   29/58     20/60
  18            Chang FH 2009 [@pone.0102372-Chang1]                  InnerMongolia                  NA                    NA                    Population                                               263 cases                                                                          263 healthy controls matched by age, gender and ethnicity                                                   152/263                                  126/263                                                                                                           
  19              Chen H 2008 [@pone.0102372-Chen2]                       Anhui                2005.9--2007.12             ALL                   Population                                   158 cases (86 SC, 36AC, 36 other)                                                                   455 controls with comparable in gender and age                                                          99/158                                  246/454                                                                                                           
  20               Liu Q 2008[@pone.0102372-Liu4]                       Shandong               2006.3--2007.5            PARTIAL                 Population                        110 cases (70 males) including 68 SC and 1 AC, 11 others                                                      125 controls (82 males) matched by age and gender                                                        66/110                                   57/125                                                                                                           
  21               Qi XS 2008 [@pone.0102372-Qi1]                         Gansu                  2005--2007                ALL                    Hospital                                    53 cases (27SC, 3 AC, 230 others)                                                              72 controls with comparable in gender and smoking status                                     [Δ](#nt103){ref-type="table-fn"}34/53    [Δ](#nt103){ref-type="table-fn"}41/72                    17/53                                   27/72                   10/53     17/72
  22               Xia Y 2008 [@pone.0102372-Xia1]                   Gansu (Qinyang)             2005--2007                ALL                    Hospital                                 58 cases (age in 40--75 years, 52 males)                                                                116 controls (age in 38--75 years, 104 males)                                                          34/58                                    61/116                                                                                                           
  23                Gu YF 2007[@pone.0102372-Gu1]                        Beijing               2000.11--2005.6             ALL             Hospital and Population                     279 cases (84 SC, 110 AC, 45 SCLC and others 40)                       684 (575 healthy controls and 109 benign pulmonary disease cases) equally with comparable in age, gender and ethnicity                     164/279                                  325/684                                                                                                           
  24             Wang YS 2007 [@pone.0102372-Wang3]                       Anhui                      NA                    ALL                   Population                                    47 NSCLC (31 SC, 7 AC, 9 others)                                                          94 healthy controls (84 males) with comparable in age and gender                                                 27/47                                    50/94                                                                                                            
  25              Lei FM 2007 [@pone.0102372-Lei1]                  Sichuan (Chengdu)          2004.1--2006.1              NA                    Population                                    42 cases (age 64.7±11.03 years)                                           103 controls (age 50.8±7.02 years) with comparable in residential township, gender and occupation                                24/42                                    57/103                                                                                                           
  26            Chang FH 2006 [@pone.0102372-Chang2]                  InnerMongolia                  NA                    ALL                    Hospital                                           163 cases (92 males)                                        163 controls without tumors, rheumaticdisease and pulmonary disease, matched by age, gender, residential township                       106/163                                   78/163                                                                                                           
  27\*           Chen HC 2006 [@pone.0102372-Chen3]                       Hunan                      NA                    ALL                   Population                    97non-smoker cases (42 males) including 51 SC, 43 AC, 3 unknown)                                      197 healthy controls (96 males) matched by age and gender in non-smokers                                             60/97                                    89/197                                   59/97                                  85/197                   36/97    44/197
  28                Li Y 2006 [@pone.0102372-Li5]                         Henan                2003.3--2003.8              ALL                   Population                              98 cases including 64 SC, 13 AC and 21 SCLC                                                                136 controls, comparable in age and gender                                                            60/98                                    60/136                                                                                                           
  29               Yao W 2006 [@pone.0102372-Yao2]                  Henan (Zhengzhou)                NA                    ALL                   Population                             77 cases including 42 SC, 24 AC and 11 others                                                                     107 healthy controls (57 males)                                                                 45/77                                    45/107                                   44/77                                  54/107                   26/77    25/107
  30             Qian BY 2006 [@pone.0102372-Qian1]                      Tianjin               2004.3--2005.3              ALL                   Population                              108 cases in han population in Tianjin city                                                  108 controls (66 males) with comparable in age and occupational status                                              69/108                                   53/108                                                                                                           
  31             Wang QM 2006 [@pone.0102372-Wang4]                        NA                        NA                  PARTIAL                 Population                               56 cases (age 64.86±12.53 years, 50 males)                                                               42 controls (age 59.12±12.51 years, 38 males)                                                          40/56                                    19/42                                                                                                            
  32                He DX 2006[@pone.0102372-He1]                   Yunnan (Kunming)                 NA                    NA                    Population                                     61 cases (age in 40--60 years)                                                                       46 healthy controls (age in 40--55 years)                                                                                                                                              33/61                                   29/46                           
  33\*           Chan EC 2005 [@pone.0102372-Chan1]                        NA                        NA                    ALL                   Population                                       75 cases (31 SC and 44 AC)                                                   162 healthy controls without history of pulmonary disease, matched by age and gender                                       31/75                                    91/162                                                                                                           
  34             Yuan TZ 2005 [@pone.0102372-Yuan1]                      Sichuan                     NA                    ALL                   Population                                   150 cases (70 SC, 61 AC, other 19)                                                         152 controls with comparable in age and gender in Han population                                                                                                                                  82/150                                  58/152                           
  35               Li DR 2005 [@pone.0102372-Li6]                        Sichuan               2001.7--2004.2              ALL                    Hospital           99 NSCLC cases (age 58.4±10.6 years,74 males) including 41 SC, 42 AC, 16 mixed style                              66 controls (age 42.4±14.9 years, 37 males) with lung benign disease.                                              57/99                                    27/66                                                                                                            
  36               Ye WY 2005 [@pone.0102372-Ye2]                 Guangdong (Guangzhou)              NA                    ALL                    Hospital                                                 58 cases                                                               62 controls without tumor and respiratory disease, comparable in age and gender                                         23/58                                    33/62                                                                                                            
  37\*           Chou YC 2005 [@pone.0102372-Chou1]                      Taiwan                1990.7--2000.12             NA                    Population                                                30 cases                                                                  60 cancer-free controls matched for gender, age and residential township                                             18/30                                    39/60                                                                                                            
  38             Liang GY 2004[@pone.0102372-Liang1]                Jiangsu (Nanjing)                NA                    ALL                    Hospital                             152 cases (107 males) including 63 SC and 89 AC                                                    152 controls without lung disease matched for gender, age (±5)                                                  82/152                                   79/152                                  85/152                                  58/152                           
  39\*           Yang XHR 2004 [@pone.0102372-Yang2]             Heilongjiang (Shenyang)       1985.9--1987.9              ALL                   Population                                               200 cases                                                                                    144 healthy controls, matched by age                                                              108/186                                   75/139                                                                                                           
  40\*        Moira CY 2004 [@pone.0102372-ChanYeung1]                  Hong Kong              1999.7--2001.6              ALL                   Population                                      229 cases (127 AC and 38 SC)                                                                       197 healthy controls, significantly younger                                                          130/229                                  117/197                                  143/229                                 102/197                          
  41\*             Lan Q 2004 [@pone.0102372-Lan1]                  Yunnan (Xuanwei)            1995.3--1996               NA                    Population                                               122 cases                                                                           122 controls matched by age, gender and smoking status                                                      82/122                                   60/122                                  73/122                                  64/122                           
  42               Gu YF 2004 [@pone.0102372-Gu2]                        Beijing                     NA                    ALL             Hospital and Population   180 cases (124 males) including 52 SA, 66 AC, 29 SCLC, 11 mixed style and 22 others    224 controls (117 controls with lung benign disease and 107 healthy controls), equally comparable in gender, age, ethnicity                  101/180                                  102/224                                                                                                           
  43             Dong CT 2004 [@pone.0102372-Dong1]                      Sichuan               2001.1--2001.11             ALL                    Hospital                                                 82 cases                                                        91 respiratory system disease controls without tumor, comparable in age, gender and ethnicity                                  48/82                                    36/91                                                                                                            
  44              Luo CL 2004 [@pone.0102372-Luo1]                      Guangzhou                    NA                    ALL                   Population                    63 cases (49 males) including 24 SC, 28 AC, 7 SCLC and 4 others                                             47 healthy controls, comparable in age, gender and ethnicity                                                   45/63                                    24/47                                                                                                            
  45              Cao YF 2004 [@pone.0102372-Cao1]                        Hunan                      NA                    ALL                   Population                                               104 cases                                                                                   205 controls, comparable in age, gender                                                             65/104                                   95/205                                  69/104                                  87/205                   43/104   46/205
  46             Chen SD 2004 [@pone.0102372-Chen4]                     Guangdong                2000--2001                NA                     Hospital                                                 91 cases                                                                                  91 controls, comparable in age and gender                                                            56/91                                    51/91                                                                                                            
  47            Huang XH 2004 [@pone.0102372-Huang1]              Guangdong (Guangzhou)        2000.10--2002.1             ALL             Hospital and Population                        91 cases including 54 SC, 31 AC and 6 SCLC                                     138 control (91 hospital patients and 47 healthy controls), matched by age, gender, and residence                                56/91                                    73/138                                                                                                           
  48               Ye WY 2004 [@pone.0102372-Ye3]                 Guangdong (Guangzhou)        2000.10--2002.1             ALL                    Hospital                         58 cases (age in 35--85 years, 38 males and 20 females)                        62 controls without respiratory disease and tumor (age in 35--85 years, 42 males),comparable in gender and age                          35/58                                    29/62                                                                                                            
  49\*           Wang JW 2003 [@pone.0102372-Wang5]                      Beijing                 1998--2000                ALL                   Population                                              112AC cases                                                                              119 healthy controls matched for age and gender                                         [Δ](#nt103){ref-type="table-fn"}69/112   [Δ](#nt103){ref-type="table-fn"}60/119                  53/112                                  54/119                   36/112   29/119
  50\*           Wang JW 2003 [@pone.0102372-Wang6]                  Beijing/Tianjin             1998--2000                ALL                   Population                              164 AC cases (112 in Beijing, 52 in Tianjin)                                                           181 cancer-free controls matched for gender and age                                                       97/164                                   90/181                                                                                                           
  51             Chen LJ 2003 [@pone.0102372-Chen5]                   Anhui (Wuhu)                   NA                    ALL                   Population                                                38 cases                                                                              99 healthy controls, comparable in age and gender                                                        24/38                                    57/99                                                                                                            
  52               Li WY 2003 [@pone.0102372-Li7]                        Beijing                     NA                    ALL                    Hospital                                                217 cases                                                                200 non-cancer controls, comparable in age, gender and township of residence                                          127/217                                   95/200                                                                                                           
  53\*             Lu WF 2002 [@pone.0102372-Lu1]            Beijing and surrounding regions   1997.1--2000.12             ALL                   Population                                     314 cases (177 SC and 137 AC)                                                             320 normal controls, matched for age, gender and smoking status                                                158/314                                  155/314                                                                                                           
  54a            Qiao GB 2002 [@pone.0102372-Qiao1]                     Guangzhou              1997.1--1999.12             ALL                    Hospital                                   213 cases (106 SC, 62 AC, 45 others)                                                                           64 with lung benign disease                                                                  130/213                                   31/64                                                                                                            
  54b            Qiao GB 2002 [@pone.0102372-Qiao1]                     Guangzhou              1997.1--1999.12             ALL                   Population                                  213 cases (106 SC, 62 AC, 45 others)                                                                                135 healthy cases                                                                       130/213                                   64/135                                                                                                           
  55            Zhang LZ 2002 [@pone.0102372-Zhang2]                Jiangsu (Xuzhou)           1999.3--2000.10             ALL                    Hospital           65 cases (age 59.4±8.4 years, 56 males) including 34 SC, 25 AC, 2 SCLC and 4 others                                            60 controls (age 55.6±7.5 years, 54 males)                                                            41/65                                    27/60                                                                                                            
  56               Shi Y 2002 [@pone.0102372-Shi3]                        Hubei                      NA                    ALL                    Hospital                                                120 cases                                                                   120 noncancer controls, comparable in age and gender in Han population                                              74/120                                   53/120                                                                                                           
  57            Zhang JK 2002 [@pone.0102372-Zhang3]              Guangdong (Guangzhou)        1999.1--2000.5              ALL                   Population                                            42 females cases                                                                          55 healthy females match by age in Han population                                        [Δ](#nt103){ref-type="table-fn"}28/42    [Δ](#nt103){ref-type="table-fn"}30/55    [Δ](#nt103){ref-type="table-fn"}19/42   [Δ](#nt103){ref-type="table-fn"}21/55   12/42     10/55
  58            Zhang JK 2002 [@pone.0102372-Zhang4]              Guangdong (Guangzhou)        1999.1--2000.5              ALL                   Population                                               161 cases                                                                             165 healthy controls, comparable in age and gender                                                        94/161                                   92/165                                  74/161                                  72/165                           
  59               Xin Y 2002 [@pone.0102372-Xin1]                       Yunnan                      NA                    NA                    Population                                                56 cases                                                                                             99 healthy controls                                                                       43/56                                    65/99                                                                                                            
  60\*          Cheng YW 2001 [@pone.0102372-Cheng1]                     Taiwan                      NA                    NA                     Hospital                                           62 nonsmoking cases                                                             20 noncancer controls with lung disease and comparable in age and gender                                             25/62                                    10/20                                                                                                            
  61\*            Chen SQ 2001[@pone.0102372-Chen6]                      Jiangsu                     NA                    ALL                   Population                                               106 cases                                                                               106 healthy controls matched for gender and age                                                         56/106                                   39/106                                                                                                           
  62\*     Stephanie J London 2000 [@pone.0102372-London1]              Shanghai               1986.1--1997.3            PARTIAL                 Population                                               234 cases                                                                            714 controls matched for age and residential township                                                     122/232                                  427/710                                  134/232                                 426/710                  85/232   275/710
  63\*          Cheng YW 2000 [@pone.0102372-Cheng2]                     Taiwan                      NA                    NA                     Hospital                                                 73 cases                                                           33 noncancer controls with lung cancer and comparable in age, gender and smoking status                                     34/73                                    17/33                                                                                                            
  64               Lan Q 1999 [@pone.0102372-Lan2]                  Yunnan (Xuanwei)           1994.7--1995.11           PARTIAL                 Population                                                86 cases                                                                              86 controls equally comparable in age and gender                                                         56/86                                    38/86                                    52/86                                   52/86                           
  65a\*            Gao Y 1999 [@pone.0102372-Gao1]                Guangdong (Guangzhou)        1996.11--1997.3             ALL                   Population                               59 cases (26 AC, 23 SC and 10 mixed style)                                                      73 healthy controls in Han population matched by age and gender                                                 34/59                                    36/73                                                                                                            
  65b\*            Gao Y 1999 [@pone.0102372-Gao1]                Guangdong (Guangzhou)        1996.11--1997.3             ALL                    Hospital                                59 cases (26 AC, 23 SC and 10 mixed style)                                               59 free-cancer controls without hereditary disease matched by age and gender                                           34/59                                    29/59                                                                                                            
  66             Chen SQ 1999 [@pone.0102372-Chen7]                      Jiangsu                     NA                    NA                    Population                                                68 cases                                                                                            105 healthy controls                                                                       39/68                                    42/105                                                                                                           
  67               Gao JR1998 [@pone.0102372-Gao2]                      Guangdong              1995.11--1996.4             ALL                   Population                                                46 cases                                                              70 controls equally comparable in age, gender, ethnicity and residential township                                        27/46                                    25/70                                                                                                            
  68a               Qu YH 1998[@pone.0102372-Qu1]                       Shanghai                     NA                    NA                    Population                                100 female cases (age 60.18±12.18 years)                                                                 95 healthy controls (age 60.48±12.29 years)                                                           56/100                                   49/94                                                                                                            
  68b              Qu YH 1998 [@pone.0102372-Qu1]                Heilongjiang (Haerbin)              NA                    NA                    Population                                   82 female cases (age 47.99±12.17)                                                                     85 healthy controls (age 47.36±11.17 years)                                                           46/82                                    45/85                                                                                                            
  69\*            Sun GF 1997 [@pone.0102372-Sun1]                      Liaoning               1992.1--1994.12             ALL                   Population                              207 cases including 86 SC, 68 AC and 53 SCLC                                                                              364 controls                                                                          147/207                                  186/364                                                                                                           
  70a\*             Ge H 1996 [@pone.0102372-Ge1]                       Hong Kong                1989--1994                ALL                   Population                      98 NSCLC cases (61 males), including 66AC, 26 SCC, 6 others)                                                                   25 healthy controls                                                                       59/89                                    16/25                                                                                                            
  70b\*             Ge H 1996 [@pone.0102372-Ge1]                       Hong Kong                1989--1994                ALL                    Hospital                                              89 NSCLC cases                                                                                      28 bronchiectasis patients                                                                    59/89                                    19/28                                                                                                            
  71              Sun GF 1995 [@pone.0102372-Sun2]                         NA                        NA                    ALL                   Population                                               175 cases                                                                                            104 healthy controls                                                                      125/175                                   54/104                                                                                                           

Pathologic diagnosis^¶^: ALL means that all lung cancer cases were confirmed by pathologic diagnosis; PARTIAL means that partial cases were confirmed by pathologic diagnosis; NA means that relative data were not available in original studies.

SC: Squamous Carcinoma; AC: Adenocarcinoma; SCLC: Small Cell Lung Carcinoma; NSCLC: Non-small-cell Lung Carcinoma. \*: Articles published in English.

: These data were omitted because of a larger sample from the same studied population by the same research group.

a/b: A study with two distinct controls encompassed population-based and hospital-based could been analyzed, respectively.

10.1371/journal.pone.0102372.t002

###### The contextual details of subgroup analysis included in this meta-analysis.

![](pone.0102372.t002){#pone-0102372-t002-2}

  No.                                                        Study                              Material used for detecting GSTs genotype          Combined evaluation of other genes       Gene                  *CYP1A1* (Msp1) HWE              Null *GSTs* genotype (%)   Non-smoker[Ф](#nt107){ref-type="table-fn"}                smoker                         Study type                   Quality score^ζ^                     
  ------------------------------------ ------------------------------------------------- -------------------------------------------------------- ------------------------------------ --------------- ------------------------------------------ -------------------------- -------------------------------------------- ---------------------------------- ------------------------------- ------------------------------- ----------- ----
                                                             2012                                                                                                                                                                                                                                                                                                                                                                        
  1                                            Liu DZ et al[@pone.0102372-Liu2]                                    WBC                                             NA                      *GSTM1*                         NA                                29.7                               42/105                                  52/175                           103/255                         55/185                  EG       8
  2                                            Wang N et al[@pone.0102372-Wang2]                                   WBC                                    *CYP1A1,mEH, XRCC1*           *GSTM1/GSTT1*                     YES                             44.1/39.1                               NA                                      NA                               NA                              NA                    EG       8
  3                                             Li WY et al[@pone.0102372-Li3]                                     WBC                                  *CYP1A1,CYP2E1, CYP2D6*            *GSTM1*                        YES                                47.0                               55/96                                   70/135                           72/121                           23/63                  EG       8
  4                                           Chen CM et al[@pone.0102372-Chen1]                                   WBC                                          *CYP1A1*                   *GSTM1*        YES[\*](#nt106){ref-type="table-fn"}               55.3                               34/54                                   47/76                            89/146                          63/113                  EG       7
  5                                            Yao ZG et al[@pone.0102372-Yao1]                                    WBC                                            *NA*                     *GSTM1*                         NA                                45.3                               29/45                                   38/78                            67/105                           30/72                  EG       8
  6                                            Liu JN et al[@pone.0102372-Liu3]                                    WBC                                            *NA*                     *GSTT1*                         NA                                41.5                               26/51                                   38/85                             31/49                           18/50                  EG       6
  7                                            Han RL et al[@pone.0102372-Han1]                                    WBC                                            *NA*                     *GSTM1*                         NA                                41.6                               26/45                                   54/115                            60/83                           35/99                  EG       5
                                                             2011                                                                                                                                                                                                                                                                                                                                                                        
  8                                            Jin YT et al [@pone.0102372-Jin1]                                   WBC                                          *CYP1A1*                   *GSTM1*      NO/YES[\*](#nt106){ref-type="table-fn"}              37.7                   OR 95% CI  = 0.76(0.18--3.17)           OR 95% CI  = 2.11(0.66--6.88)                  EG                               6                            
  9                                              Ai C et al[@pone.0102372-Ai1]                                     WBC                                            *NA*                     *GSTM1*                         NA                                46.0                                 NA                                      NA                               NA                              NA                    EG       8
  10                                         Zhang JQ et al[@pone.0102372-Zhang1]                                  WBC                                            *NA*                     *GSTM1*                         NA                                44.0                               13/22                                    9/24                             21/28                           13/26                  EG       7
  11                                            Du GB et al[@pone.0102372-Du1]                                     WBC                                            *NA*                     *GSTM1*                         NA                                56.8                               32/49                                   46/82                             41/76                           23/43                  EG       6
  12                                             Li Y et al[@pone.0102372-Li4]                       cases: BALF cells, controls: WBC                           *CYP1A1*                   *GSTM1*      YES/YES[\*](#nt106){ref-type="table-fn"}             44.2                               20/27                                   28/64                             43/76                           33/74                  EG       7
  13                                           Bai TY et al[@pone.0102372-Bai1]                                     NA                                            *NA*                     *GSTT1*                         NA                                44.4                               24/63                                   20/71                             32/76                           30/40                  NA       4
                                                             2010                                                                                                                                                                                                                                                                                                                                                                        
  14                                           Jin YT et al[@pone.0102372-Jin2]                                    WBC                                          *CYP1A1*                   *GSTM1*                         NA                                52.7                               25/37                                   28/63                            70/113                           51/87                  EG       7
  15                                         Zheng DJ et al[@pone.0102372-Zheng1]                                  WBC                                            *NA*                     *GSTM1*                         NA                                57.0                                 NA                                      NA                               NA                              NA                    EG       8
  16                                           Zhu XX et al[@pone.0102372-Zhu1]                                    WBC                                          *CYP1A1*                   *GSTM1*      YES/YES[\*](#nt106){ref-type="table-fn"}             45.0                                 NA                                      NA                               NA                              NA                    EG       8
  17                                            Fan J et al[@pone.0102372-Fan1]                                    WBC                                            *NA*                     *GSTM1*                         NA                                55.0                               23/32                                   22/40                             17/26                           11/20                  EG       7
                                                                                                                                                                                           *GSTT1*                         NA                                48.3                               20/32                                   21/41                             18/26                           8/19                   EG      
                                                             2009                                                                                                                                                                                                                                                                                                                                                                        
  18                                         Chang FH et al[@pone.0102372-Chang1]                                  WBC                                          *CYP1A1*                   *GSTM1*                         NA                                47.9                               60/97                                  101/145                           92/166                          25/118                  EG       7
                                                             2008                                                                                                                                                                                                                                                                                                                                                                        
  19                                           Chen H et al[@pone.0102372-Chen2]                                   WBC                                          *CYP1A1*                   *GSTM1*                         NO                                54.2                               26/39                                  126/246                           73/119                          120/208                 EG       8
  20                                            Liu Q et al[@pone.0102372-Liu4]                                    WBC                                          *CYP1A1*                   *GSTM1*                         NO                                45.6                                 NA                                      NA                               NA                              NA                    EG       8
  21[Ψ](#nt110){ref-type="table-fn"}            Qi XS et al[@pone.0102372-Qi1]                                     WBC                                            *NA*                     *GSTT1*                         NA                                37.5                                0/5                                     4/13                             17/47                           23/59                  EG       7
                                                                                                                                                                                           *GSTM1*                         NA                                56.9                                 NA                                      NA                               NA                              NA                            
  22                                            Xia Y et al[@pone.0102372-Xia1]                                    WBC                                          *CYP1A1*                   *GSTM1*                        YES                                37.5                                 NA                                      NA                               NA                              NA                    EG       6
                                                             2007                                                                                                                                                                                                                                                                                                                                                                        
  23                                            Gu YF et al[@pone.0102372-Gu1]                                     WBC                                      *CYP1A1,2D6,2E1*               *GSTM1*                         NA                                47.5                                 NA                                      NA                               NA                              NA                    EG       7
  24[‡](#nt109){ref-type="table-fn"}          Wang YS et al[@pone.0102372-Wang3]                        WBC/Adjacent normal tissue                                *NA*                     *GSTM1*                         NA                                53.2                   OR 95% CI  = 1.07(0.19--5.96)                       OR = 1                OR 95% CI  = 1.57(0.48--5.27)   OR 95% CI  = 1.29(0.37--4.68)      EG       7
  25                                           Lei FM et al[@pone.0102372-Lei1]                                    WBC                                            *NA*                     *GSTM1*                         NA                                55.3                                 NA                                      NA                               NA                              NA                    EG       8
                                                             2006                                                                                                                                                                                                                                                                                                                                                                        
  26                                         Chang FH et al[@pone.0102372-Chang2]                                  WBC                                          *CYP1A1*                   *GSTM1*                         NA                                47.9                               44/62                                   62/96                            62/101                           16/67                  EG       6
  27                                          Chen HC et al[@pone.0102372-Chen3]                                   WBC                                        *NAT2,GSTP1*                 *GSTM1*                         NA                                45.2                                 NA                                      NA                               NA                              NA                    EG       7
                                                                                                                                                                                           *GSTT1*                         NA                                43.1                                 NA                                      NA                               NA                              NA                    EG      
  28                                             Li Y et al[@pone.0102372-Li5]                        case: BALF cells control: WBC                             *CYP1A1*                   *GSTM1*      YES/YES[\*](#nt106){ref-type="table-fn"}             44.1                               19/26                                   28/63                             41/72                           32/73                  EG       8
  29                                            Yao W et al[@pone.0102372-Yao2]                   case: lung cancer tissue/control: WBC                           *NA*                     *GSTM1*                         NA                                42.1                                 NA                                      NA                               NA                              NA                    NEG      NA
                                                                                                                                                                                           *GSTT1*                         NA                                50.5                                 NA                                      NA                               NA                              NA                             NA
  30                                          Qian BY et al[@pone.0102372-Qian1]                                    NA                                          *CYP1A1*                   *GSTM1*                        YES                                49.1                               15/23                                   22/46                             54/85                           31/62                  NEG      NA
  31                                          Wang QM et al[@pone.0102372-Wang4]                                   WBC                                          *CYP2C9*                   *GSTM1*                         NA                                45.2                               10/19                                    7/19                             30/37                           12/23                  EG       4
  32                                            He DX et al[@pone.0102372-He1]                                     WBC                                            *NA*                     *GSTT1*                         NA                                63.0                                 NA                                      NA                               NA                              NA                    EG       5
                                                             2005                                                                                                                                                                                                                                                                                                                                                                        
  33                                          Chan EC et al[@pone.0102372-Chan1]                case: uninvolved lung tissue/control: WBC                  *GSTP1, MPO etc.*               *GSTM1*                         NA                                56.2                                 NA                                      NA                               NA                              NA                    EG       5
  34                                          Yuan TZ et al[@pone.0102372-Yuan1]                                   WBC                                            *NA*                     *GSTT1*                         NA                                38.2                               12/52                                   39/100                            70/98                           19/52                  EG       7
  35                                            Li DR et al[@pone.0102372-Li6]                                     WBC                                          *CYP2E1*                   *GSTM1*                         NA                                40.9                               22/36                                   17/50                             35/63                           10/16                  EG       5
  36                                            Ye WY et al[@pone.0102372-Ye2]                                     WBC                                            *NA*                     *GSTM1*                         NA                                53.2                                 NA                                      NA                               NA                              NA                    EG       6
  37                                          Chou YC et al[@pone.0102372-Chou1]                                   WBC                                            *NA*                     *GSTM1*                         NA                                65.0                                 NA                                      NA                               NA                              NA                    EG       8
                                                             2004                                                                                                                                                                                                                                                                                                                                                                        
  38                                         Liang GY et al[@pone.0102372-Liang1]                                  WBC                                 *CYP1A1, 2E1, GSTP1 etc.*        *GSTM1/GSTT1*                     YES                             52.0/38.2                               NA                                      NA                               NA                              NA                    EG       6
  39                                          Yang XHR et al[@pone.0102372-Yang2]                                  WBC                                          *CYP1A1*                   *GSTM1*                         NA                                54.0                   OR 95% CI  = 1.05(0.56--2.00)           OR 95% CI  = 1.61(0.80--3.25)                  EG                               7                            
  40                                       Moira CY et al[@pone.0102372-ChanYeung1]                                WBC                                          *GSTP1*                    *GSTM1*                         NA                                59.4                                 NA                                      NA                               EG                               6                            
                                                                                                                                                                                           *GSTT1*                         NA                                51.8                 OR ^a^ 95% CI  = 2.18(1.21--3.94)                       NA                                                                                             
  41                                            Lan Q et al[@pone.0102372-Lan1]                                buccal cells                                      *p53*                  *GSTM1/GSTT1*                      NA                             49.2/52.5                               NA                                      NA                               NA                              NA                    NEG      NA
  42                                            Gu YF et al[@pone.0102372-Gu2]                                     WBC                                     *CYP1A1, 2D6, 2E1*              *GSTM1*                         NA                                45.5                    OR 95% CI  = 2.01(0.53,8.22)          OR 95% CI  = 5.50(1.43,22.89)^I^                EG                               5                            
  43                                          Dong CT et al[@pone.0102372-Dong1]                                   WBC                                          *CYP1A1*                   *GSTM1*                         NA                                39.6                                 NA                                      NA                               NA                              NA                    EG       7
  44                                           Luo CL et al[@pone.0102372-Luo1]                                    WBC                                           *p53*                     *GSTM1*                         NA                                51.1                                 NA                                      NA                               NA                              NA                    EG       6
  45                                           Cao YF et al[@pone.0102372-Cao1]                                    WBC                                            *NA*                  *GSTM1/GSTT1*                      NA                             46.3/42.4                               NA                                      NA                               NA                              NA                    EG       7
  46                                          Chen SD et al[@pone.0102372-Chen4]                                   WBC                                          *CYP2E1*                   *GSTM1*                         NA                                56.0                               25/36                                   31/59                             31/55                           18/32                  EG       7
  47                                         Huang XH et al[@pone.0102372-Huang1]                                  WBC                                            *NA*                     *GSTM1*                         NA                                52.9                               25/36                                   39/76                             31/55                           34/62                  EG       7
  48                                            Ye WY et al[@pone.0102372-Ye3]                                     WBC                                            *NA*                     *GSTM1*                         NA                                46.8                                 NA                                      NA                               NA                              NA                    EG       7
                                                             2003                                                                                                                                                                                                                                                                                                                                                                        
  49[Ψ](#nt110){ref-type="table-fn"}          Wang JW et al[@pone.0102372-Wang5]                                   WBC                                          *GSTP1*                    *GSTM1*                         NA                                50.4                               40/64                                   36/71                             29/48                           24/48                  EG       6
                                                                                                                                                                                           *GSTT1*                         NA                                49.7                               30/64                                   27/71                             23/48                           27/48                          
  50                                          Wang JW et al[@pone.0102372-Wang6]                                   WBC                                       *CYP2E1, 1A1*                 *GSTM1*                        YES                                57.6                               53/94                                   52/105                            44/70                           38/76                  EG       8
  51                                          Chen LJ et al[@pone.0102372-Chen5]                                   WBC                                            *NA*                     *GSTM1*                         NA                                47.5                                8/13                                   36/63                             16/25                           21/36                  EG       7
  52                                            Li WY et al[@pone.0102372-Li7]                                     WBC                                     *CYP1A1,2E1, 2D6*               *GSTM1*                        YES                                50.4                               55/96                                   70/135                           72/121                           25/65                  EG       6
                                                             2002                                                                                                                                                                                                                                                                                                                                                                        
  53                                            Lu WF et al[@pone.0102372-Lu1]             case: "normal" tissue adjacent to tumor/control: WBC                  *MPO*                     *GSTM1*                         NA                                49.4                               54/111                                 154/298                           104/203                         156/330                 EG       8
  54a                                         Qiao GB et al[@pone.0102372-Qiao1]              case: tumor tissue/control: benign lung tissue                      *NA*                     *GSTM1*                         NA                                48.4                                 NA                                      NA                               NA                              NA                    EG       7
  54b                                         Qiao GB et al[@pone.0102372-Qiao1]                     case: tumor tissue/control: WBC                              *NA*                     *GSTM1*                         NA                                47.4                                 NA                                      NA                               NA                              NA                    EG       6
  55                                         Zhang LZ et al[@pone.0102372-Zhang2]                 case: lung cancer tissue/control: WBC                         *CYP1A1*                   *GSTM1*                         NA                                45.0                                8/14                                   14/28                             33/51                           13/32                  NEG      NA
  56                                            Shi Y et al[@pone.0102372-Shi3]                                    WBC                                          *CYP2E1*                   *GSTM1*                         NA                                44.2                                 NA                                      NA                               NA                              NA                    EG       6
  57[Ψ](#nt110){ref-type="table-fn"}         Zhang JK et al[@pone.0102372-Zhang3]                                  WBC                                            *NA*                     *GSTM1*                         NA                                54.5                               28/38                                   23/44                              NA                              NA                 Female/EG   7
                                                                                                                                                                                           *GSTT1*                         NA                                38.2                               18/38                                   18/44                              NA                              NA                            
  58                                         Zhang JK et al[@pone.0102372-Zhang4]                                  WBC                                            *NA*                     *GSTM1*                         NA                                55.8                               39/57                                   52/100                             NA                              NA                    EG       7
                                                                                                                                                                                           *GSTT1*                         NA                                43.6                               27/57                                   44/100                             NA                              NA                            
  59                                            Xin Y et al[@pone.0102372-Xin1]                                    WBC                                            *NA*                     *GSTM1*                         NA                                65.7                                 NA                                      NA                               NA                              NA                    EG       4
                                                             2001                                                                                                                                                                                                                                                                                                                                                                        
  60                                         Cheng YW et al[@pone.0102372-Cheng1]         case: normal tissue surrounding lung tumor/control: NA                  *NA*                     *GSTM1*                         NA                                50.0                                 NA                                      NA                               NA                              NA                    NEG      NA
  61                                          Chen SQ et al[@pone.0102372-Chen6]                                   WBC                                          *CYP1A1*                   *GSTM1*                         NA                                36.8                                 NA                                      NA                              42/80                           29/80                  EG       7
                                                             2000                                                                                                                                                                                                                                                                                                                                                                        
  62                                    Stephanie J London et al[@pone.0102372-London1]                            WBC                                            *NA*                  *GSTM1/GSTT1*                      NA                             60.1/60.0                               NA                                      NA                               NA                              NA                    EG       7
  63                                         Cheng YW et a[@pone.0102372-Cheng2]l                         non-tumorous area cell                                *CYP1A1*                   *GSTM1*                        YES                                51.5                                 NA                                      NA                               NA                              NA                    NEG      NA
                                                             1999                                                                                                                                                                                                                                                                                                                                                                        
  64                                            Lan Q et al[@pone.0102372-Lan2]                                buccal cells                                       *NA*                   GSTM1/GSTT1                       NA                             44.2/60.5                               NA                                      NA                               NA                              NA                    NEG      NA
  65a                                           Gao Y et al[@pone.0102372-Gao1]                                     NA                                            *NA*                     *GSTM1*                         NA                                49.3                               14/21                                   26/51                             20/38                           10/22                  EG       8
  65b                                           Gao Y et al[@pone.0102372-Gao1]                                     NA                                            *NA*                     *GSTM1*                         NA                                49.2                               14/21                                   20/34                             20/38                           9/25                   EG       7
  66                                          Chen SQ et al[@pone.0102372-Chen7]                                   WBC                                          *CYP1A1*                   *GSTM1*                         NA                                40.0                                 NA                                      NA                               NA                              NA                    EG       5
                                                             1998                                                                                                                                                                                                                                                                                                                                                                        
  67                                           Gao JR et al[@pone.0102372-Gao2]                                    WBC                                          *CYP2D6*                   *GSTM1*                         NA                                35.7                                 NA                                      NA                               NA                              NA                    EG       8
  68a                                           Qu YH et al[@pone.0102372-Qu1]                                     WBC:                                         *CYP1A1*                   *GSTM1*                        YES                                52.1                               56/100                                  49/94                              NA                              NA                 Female/EG   5
  68b                                           Qu YH et al[@pone.0102372-Qu1]                                     WBC                                          *CYP1A1*                   *GSTM1*                        YES                                52.9                               46/82                                   45/85                              NA                              NA                 Female/EG   4
                                                             1997                                                                                                                                                                                                                                                                                                                                                                        
  69                                           Sun GF et al[@pone.0102372-Sun1]                                    WBC                                            *NA*                     *GSTM1*                         NA                                51.1                               49/67                                   97/191                           98/140                          89/173                  EG       6
                                                             1996                                                                                                                                                                                                                                                                                                                                                                        
  70a                                            Ge H et al[@pone.0102372-Ge1]                  case: normal lung tissue, WBC/control: WBC                      *L-myc*                    *GSTM1*                         NA                                64.0                                 NA                                      NA                               NA                              NA                    EG       6
  70b                                            Ge H et al[@pone.0102372-Ge1]                  case: normal lung tissue, WBC/control: WBC                      *L-myc*                    *GSTM1*                         NA                                67.9                                 NA                                      NA                               NA                              NA                    EG       5
                                                             1995                                                                                                                                                                                                                                                                                                                                                                        
  71                                           Sun GF et al[@pone.0102372-Sun2]                                    WBC                                            *NA*                     *GSTM1*                         NA                                51.9                               36/52                                   38/74                            89/123                           16/30                  EG       5

HWE: Hardy-Weinberg Equilibrium; WBC: White blood cells; BALF: bronchoalveolar lavage fluid; NA: not available.

\*: The HWE test results of *CYP1A1* Msp1 that could be calculated were shown in the table, and the items with \* meant the result that had been reported in the articles.

: Due to different setting of smoking status in papers, people who had smoked were calculated as smokers.

OR^a^: Adjusted OR. ED: Epidemiological Design; NED: Non-epidemiology Design; WBC: blood, White blood cell lymphocytes, and serum. ^ζ^: Newcastle-Ottawa Scale (NOS).

: The OR 95% CI was captured from logistic analysis; I: Heavy-smoker; a: healthy control; b: hospital control.

: The *GSTM1* data of this study was omitted because of a bigger sample in the other study published in the same year.

4. Statistical analysis {#s2d}
-----------------------

\(1\) The pooled ORs and 95% CIs were determined by the Z test, *P*≤0.05 was considered statistically significant. (2) Statistical heterogeneity among studies was assessed by *Q* and *I^2^* statistics [@pone.0102372-Higgins1]. In heterogeneity tests, when *P*≤0.1, a random-effects model was used; when *P*\>0.1, a fixed-effects model was performed [@pone.0102372-Hedges1]. Meanwhile, if *I^2^*≥50%, 50%\>*I^2^*≥25% or *I^2^*\<25%, we identified the studies as high, middle or low heterogeneity, respectively. (3) Sensitivity analysis was performed by removing one study at a time to calculate the overall homogeneity and effect size; the Galbraith plot was also performed to examine the possible distinct articles. (4) The possible reasons for heterogeneity between studies were investigated by subgroup analyses. Nine subgroups were analyzed as follows: histopathological classification (SC, AC or SCLC), geographical location (North, Northeast, Northwest, East, Central, South, or Southwest of China) (See [Figure S1](#pone.0102372.s002){ref-type="supplementary-material"}), smoking status (smoker *vs*. non-smoker), *CYP1A1*(Msp1) polymorphisms, case number (\<100 *vs*. ≥100), source of controls (population-based *vs*. hospital-based), research design (epidemiological design *vs*. non-epidemiological design), test material (white blood cells, involved tissues or other cells, or not available) and quality score (4--5, 6, 7--8). The last five items listed above were used to assess the study quality. (5) Cumulative meta-analysis was used to explore any significant changes in the variation of sample size or publication year. (6) Publication bias was investigated by the Begg\'s test [@pone.0102372-Begg1], Egger\'s linear regression test and Trim and Fill test [@pone.0102372-Egger1]. (7) All analyses were performed with the software Stata version 12.0 (StataCorp LP, College Station, Texas, USA), and all *P* values were two sided.

Results {#s3}
=======

1. Study selection and study characteristics {#s3a}
--------------------------------------------

We ultimately identified a total of 71 articles [@pone.0102372-Liu2]--[@pone.0102372-Sun2] reporting the relationship between *GSTM1* and/or *GSTT1* genetic polymorphisms and lung cancer risk from both Chinese and English databases ([Figure 1](#pone-0102372-g001){ref-type="fig"}). There were 68 studies about *GSTM1* (8649 cases and 10380 controls) [@pone.0102372-Liu2]--[@pone.0102372-Yao1], [@pone.0102372-Han1]--[@pone.0102372-Li4], [@pone.0102372-Jin2]--[@pone.0102372-Liu4], [@pone.0102372-Xia1]--[@pone.0102372-Wang4], [@pone.0102372-Chan1], [@pone.0102372-Li6]--[@pone.0102372-Ye3], [@pone.0102372-Wang6]--[@pone.0102372-Shi3], [@pone.0102372-Zhang4]--[@pone.0102372-Sun2] published between 1995 and 2012, 17 studies about *GSTT1* (2109 cases and 3031 controls) [@pone.0102372-Wang2], [@pone.0102372-Liu3], [@pone.0102372-Bai1], [@pone.0102372-Fan1], [@pone.0102372-Qi1], [@pone.0102372-Chen3], [@pone.0102372-Yao2], [@pone.0102372-He1], [@pone.0102372-Yuan1], [@pone.0102372-Liang1], [@pone.0102372-ChanYeung1], [@pone.0102372-Lan1], [@pone.0102372-Cao1], [@pone.0102372-Wang6], [@pone.0102372-Zhang4], [@pone.0102372-London1], [@pone.0102372-Lan2] between 1999 and 2012 and 8 studies about both *GSTM1* and *GSTT1* (775 cases and 1495 controls) [@pone.0102372-Fan1], [@pone.0102372-Qi1], [@pone.0102372-Chen3], [@pone.0102372-Yao2], [@pone.0102372-Cao1], [@pone.0102372-Wang5], [@pone.0102372-Zhang3], [@pone.0102372-London1] between 2000 and 2010.

![Study flow chart.](pone.0102372.g001){#pone-0102372-g001}

Most studies were published in Chinese (49/68 of *GSTM1* studies, 13/17 of *GSTT1*, and 5/8 of both *GSTM1* and *GSTT1*). According to our criterion, 61 (89.7%) studies of *GSTM1*, 13 (76.5%) of *GSTT1*, and 7 (87.5%) of both *GSTM1* and *GSTT1* were evaluated as epidemiological designs. In both control and case groups, 50 (73.5%) studies of *GSTM1*, 13 (76.5%) of *GSTT1* and 7 (87.5%) of both *GSTM1* and *GSTT1* used white blood cells for GSTs genotype detection. The rest of the studies used adjacent lung tissue, tumor tissue, BALF cells or buccal cells, etc., for GSTs genotype detection in cases or controls. Only two studies reported the HWE test results for the *GSTM1* or *GSTT1* and satisfied HWE [@pone.0102372-Chen1], [@pone.0102372-Li5]. In the eligible studies, the null genotype frequency of *GSTM1* and *GSTT1* ranged from 29.7% to 67.9% (Mean = 49.5%) and 37.5% to 63.0% (Median = 44.4%), respectively. The *CYP1A1* (Msp1) polymorphisms satisfied the HWE in the controls of 15 (68%) studies about *GSTM1* and *CYP1A1* (Msp1). More details are shown in [Table 1](#pone-0102372-t001){ref-type="table"}, [Table 2](#pone-0102372-t002){ref-type="table"} and [Figure 2](#pone-0102372-g002){ref-type="fig"}.

![Cases and controls of 71 published studies included in this meta-analysis.\
(a) 68 literatures about *GSTM1* genetic variants and lung cancer risk; (b) 17 literatures about *GSTT1* genetic variants and lung cancer risk; (c) 8 literatures about *GSTM1*-*GSTT1* genetic variants dual null genotype and lung cancer risk.](pone.0102372.g002){#pone-0102372-g002}

2. Synthesis results of all studies {#s3b}
-----------------------------------

The results showed a significant association between the *GSTM1* null genotype and lung cancer risk in the Chinese population under the random-effects model (OR = 1.20, 95% CI: 1.16 to 1.25, *I^2^* = 45.1%, *P*\<0.001) ([Table 3](#pone-0102372-t003){ref-type="table"}). The random-effects model showed that the *GSTT1* null genotype was significantly correlated with lung cancer risk in the Chinese population (OR = 1.17, 95% CI: 1.07 to 1.28, *I^2^* = 55.9%, *P*\<0.001) ([Table 4](#pone-0102372-t004){ref-type="table"}). Further analyses showed that dual-null genotype of *GSTM1-GSTT1* had a significant higher association with lung cancer risk (OR = 1.29, 95% CI: 1.03 to 1.63, *I^2^* = 61.7%, *P* = 0.011) ([Table 5](#pone-0102372-t005){ref-type="table"}). Risk estimation for each study is shown in the Forest plots in [Figure 3](#pone-0102372-g003){ref-type="fig"}, [Figure 4a](#pone-0102372-g004){ref-type="fig"} and [Figure 4b](#pone-0102372-g004){ref-type="fig"}.

![Association between *GSTM1* null genotype and lung cancer susceptibility analyzed by the Forest plot.\
The Forest plots of pooled OR with 95% CI (Null genotype *vs*. Present genotype; OR = 1.20, 95% CI: 1.16 to 1.25; Random-effects model, *P*\<0.001).](pone.0102372.g003){#pone-0102372-g003}

![(a) Association between *GSTT1* null genotype and lung cancer susceptibility analyzed by the Forest plot. The Forest plots of pooled OR with 95% CI (Null genotype *vs*. Present genotype; OR = 1.17, 95% CI: 1.07 to 1.28; Random-effects model, *P*\<0.001). (b) Association between *GSTM1-GSTT1* dual-null genotype and lung cancer susceptibility analyzed by the Forest plot The Forest plots of pooled OR with 95% CI (Dual-null genotype *vs*. Present genotype; OR = 1.29, 95% CI: 1.03 to 1.63; Random-effects model, *P*\<0.001).](pone.0102372.g004){#pone-0102372-g004}

10.1371/journal.pone.0102372.t003

###### Subgroup analysis of the association between *GSTM1* null genotype and lung cancer risk.

![](pone.0102372.t003){#pone-0102372-t003-3}

  Polymorphism                         Null *vs*. Present                         No. of studies (cases/controls)       Odds ratio          M      Heterogeneity   *P~E~*            
  -------------- --------------------------------------------------------------- --------------------------------- -------------------- --------- --------------- -------- --------- ---------------------------------------
  *GSTM1*                                  All studies                                    68(8649/10380)            1.20\[1.16,1.25\]    \<0.001         R          45.1    \<0.001                   0.245
                       subgroup analyses by histopathology classification.                                                                                                           
                                       Squamous Carcinoma                                  14(1088/3218)            1.20\[1.12,1.27\]    \<0.001         F          19.5     0.241                    0.790
                                         Adenocarcinoma                                    13(1060/3093)            1.14\[1.03, 1.26\]    0.008          R          50.3     0.020                    0.491
                                    Small Cell Lung Carcinoma                               5(179/1853)             1.29\[1.13,1.47\]    \<0.001         F          38.7     0.163                    0.313
                          subgroup analyses by geographical location^¤^                                                                                                              
                                           North China                                     11(2320/2792)            1.19\[1.13,1.25\]    \<0.001         F          35.6     0.114                    0.099
                                       Northeast of China                                   4(835/948)              1.24\[1.07,1.43\]     0.004          R          54.1     0.088                    0.252
                                       Northwest of China                                    1(58/116)              1.11\[0.85,1.47\]     0.442          R          <@>       <@>                      <@>
                                           East China                                      16(1745/2615)            1.11\[1.02,1.20\]     0.011          R          40.8     0.045                    0.387
                                          Central China                                     8(968/1319)             1.35\[1.25,1.47\]    \<0.001         F           0       1.000                    0.050
                                           South China                                     15(1577/1276)            1.13\[1.05,1.21\]    \<0.001         F          25.5     0.174                    0.221
                                       Southwest of China                                   9(737/904)              1.21\[1.04,1.40\]     0.011          R          61.6     0.008                    0.646
                               subgroup analyses by smoking status                                                                                                                   
                             smoker[•](#nt115){ref-type="table-fn"}                          32(NA/NA)              1.34\[1.23,1.47\]    \<0.001         R          53.8    \<0.001   0.008[‡](#nt113){ref-type="table-fn"}
                                           non-smoker                                        35(NA/NA)              1.20\[1.13,1.26\]    \<0.001         F          14.6     0.226                    0.052
                               subgroup analyses by *CYP1A1*(Msp1)                                                                                                                   
                                              wt/wt                                         11(578/961)             1.17\[1.06,1.30\]     0.002          F           0       0.891                    0.678
                                              wt/mt                                         10(732/926)             1.23\[1.12,1.35\]    \<0.001         F          12.7     0.326                    0.631
                                              mt/mt                                         6(203/167)              1.34\[1.13,1.59\]     0.001          F           0       0.979    0.010[‡](#nt113){ref-type="table-fn"}
                               subgroup analyses by number of case                                                                                                                   
                                              \<100                                        32(2152/2576)            1.20\[1.12,1.28\]    \<0.001         R          35.5     0.026                    0.582
                                              ≥100                                         36(6497/7804)            1.20 \[1.15,1.26\]   \<0.001         R          52.6    \<0.001   0.024[‡](#nt113){ref-type="table-fn"}
                             subgroup analyses by source of control                                                                                                                  
                                        Population-based                                   45(5883/7304)            1.21\[1.15,1.27\]    \<0.001         R          53.3    \<0.001                   0.026
                                         Hospital-based                                    20(2216/2030)            1.20\[1.13,1.27\]    \<0.001         F          30.1     0.101                    0.150
                                           Mixed-based                                      3(550/1046)             1.22\[1.11,1.35\]    \<0.001         F           0       0.893                    0.603
                              subgroup analyses by research design                                                                                                                   
                                      Epidemiological study                                61(8056/9844)            1.20\[1.15,1.24\]    \<0.001         R          46.4    \<0.001                   0.175
                                    Non-epidemiological study                               7(593/536)              1.30\[1.16,1.45\]    \<0.001         F          19.1     0.284    0.046[‡](#nt113){ref-type="table-fn"}
                               subgroup analyses by test material                                                                                                                    
                                        White blood cells                                  50(6697/8616)            1.21\[1.16,1.26\]    \<0.001         R          46.7    \<0.001                   0.069
                     Involved tissue or cell[†](#nt114){ref-type="table-fn"}               15(1726/1524)            1.17\[1.06,1.30\]     0.003          R          52.2     0.009                    0.554
                                          Not available                                     3(226/240)              1.23\[1.04,1.45\]     0.014          F           0       0.822                    0.115
                  subgroup analyses by quality score^¶^ (Epidemiological study)                                                                                                      
                                              4--5                                         11(1108/1223)            1.20\[1.07,1.36\]     0.002          R           57      0.010                    0.606
                                                6                                          13(1948/1960)            1.15\[1.06,1.26\]     0.002          R          52.8     0.013                    0.240
                                              7--8                                         44(5593/7197)            1.21\[1.16,1.27\]    \<0.001         R          40.9     0.003    0.023[‡](#nt113){ref-type="table-fn"}

¤: Geographical locations of China were divided into 7 parts: Northeast of China (Jilin province, Liaoning province, Heilongjiang province), North China (Beijing city, Tianjin city, Heber province, Shanxi Province (Taiyuan), Inner Mongolia), East China (Shanghai city, Anhui province, Jiangxi province, Jiangsu province, Zhejiang province, Fujian province, Shandong province, Taiwan), Central China (Henan province, Hubei province, Hunan province), South China (Guangdong province, Hainan province, Guangxi Zhuang Autonomous Region, Hongkong), Southwest of China (Chongqing City, Guizhou province, Sichuan Province, Yunnan Province, Tibet), Northwest of China (Shanxi province (xi\'an), Gansu province, Ningxia Hui Autonomous Region, Xinjiang Uyghur autonomous region).

M: model of meta-analysis; R: random-effects model; F: fixed-effects model.*P~H~*: *p* value of heterogeneity test. *P~E~*:*p* value of Egger\'s test.*P~OR~*: *P*\<0.001 replace *P* = 0.000 and *P* less than 0.001. @: *p* values could not be calculated.

: the publication bias was detected in this group. ^¶^: Newcastle-Ottawa Scale (NOS).

: test materials of case or control was from the normal lung tissues, BALF cells, buccal cells or lung cancer tissue.

:the study of Wang YS et al was not included because of the unavailable data.

10.1371/journal.pone.0102372.t004

###### Subgroup analysis of the association between *GSTT1* null genotype and lung cancer risk.

![](pone.0102372.t004){#pone-0102372-t004-4}

  Polymorphism                         Null *vs*. Present                         No.ofstudies (cases/controls)       Odds ratio           M      Heterogeneity   *P~E~*            
  -------------- --------------------------------------------------------------- ------------------------------- --------------------- --------- --------------- -------- --------- -------
  *GSTT1*                                  All studies                                    17(2109/3031)            1.17\[1,07,1.28\]    \<0.001         R          55.9     0.003    0.510
                       subgroup analyses by histopathology classification                                                                                                           
                                       Squamous Carcinoma                                  5(240/680)              1.38\[1.20,1.59\]    \<0.001         F          38.9     0.162    0.222
                                         Adenocarcinoma                                    4(389/620)              1.23\[1.08,1.40\]     0.001          F           0       0.546    0.993
                                    Small Cell Lung Carcinoma                                  NA                         NA              NA           NA           NA       NA       NA
                          subgroup analyses by geographical location^¤^                                                                                                             
                                           North China                                     2(218/369)              1.05\[0.88,1.27\]     0.576          F           0       0.922     <@>
                                       Northeast of China                                      NA                         NA              NA           NA           NA       NA       NA
                                       Northwest of China                                   1(53/72)               0.86\[0.52,1.40\]     0.534         <@>         <@>       <@>      <@>
                                           East China                                      2(384/862)             1.17\[0.77,1.77\]\]    0.454          R          88.9     0.003     <@>
                                          Central China                                    4(487/765)              1.30\[1.09,1.54\]     0.003          R          55.4     0.081    0.485
                                           South China                                     3(448/422)              1.17\[1.03,1.33\]     0.013          F           0       0.440    0.876
                                       Southwest of China                                  4(419/406)              1.10\[0.90,1.35\]     0.341          R          59.4     0.060    0.487
                               subgroup analyses by smoking status                                                                                                                  
                                             smoker                                        6(344/268)              1.15\[0.73,1.81\]     0.541          R          85.8    \<0.001   0.301
                                           non-smoker                                       8(NA/NA)               1.16\[0.93,1.45\]     0.187          R          41.7     0.100    0.596
                               subgroup analyses by number of case                                                                                                                  
                                              \<100                                        6(432/568)              1.11\[0.94,1.32\]     0.221          R          49.8     0.077    0.327
                                              ≥100                                        11(1677/2463)            1.19\[1.08,1.33\]     0.001          R          61.8     0.004    0.094
                             subgroup analyses by source of control                                                                                                                 
                                        Population-based                                  14(1798/2557)            1.17\[1.07,1.29\]     0.001          R          57.7     0.004    0.284
                                         Hospital-based                                    3(311/474)              1.15\[0.86,1.54\]     0.335          R          62.2     0.071    0.587
                              subgroup analyses by research design                                                                                                                  
                                      Epidemiological study                               13(1718/2466)            1.20\[1.07,1.34\]     0.001          R          64.9     0.001    0.464
                                    Non-epidemiological study                              3(285/315)              1.09\[0.95,1.26\]     0.214          F           0       0.695    0.971
                               subgroup analyses by test material                                                                                                                   
                                        White blood cells                                 13(1718/2466)            1.20\[1.07,1.34\]     0.001          R          64.9     0.001    0.464
                                    Involved tissue or cell†                               3(285/315)              1.09\[0.95,1.26\]     0.214          F           0       0.695    0.971
                                          Not available                                    1(106/250)              1.06\[0.83,1.36\]     0.628         <@>         <@>       <@>      <@>
                  subgroup analyses by quality score^¶^ (Epidemiological study)                                                                                                     
                                              4--5                                         4(366/525)              1.07\[0.94,1.22\]     0.310          F           0       0.510    0.158
                                                6                                          4(593/603)              1.26\[1.13,1.41\]    \<0.001         F          23.1     0.272    0.860
                                              7--8                                        9(1150/1903)             1.18\[1.03,1.36\]     0.020          R          69.6     0.001    0.380

¤: geographical locations of China were divided into 7 parts: Northeast of China (Jilin province, Liaoning province, Heilongjiang province), North China (Beijing city, Tianjin city, Heber province, Shanxi Province (Taiyuan), Inner Mongolia), East China (Shanghai city, Anhui province, Jiangxi province, Jiangsu province, Zhejiang province, Fujian province, Shandong province,Taiwan), Central China (Henan province, Hubei province, Hunan province), South China (Guangdong province, Hainan province, Guangxi Zhuang Autonomous Region, Hongkong), Southwest of China (Chongqing City, Guizhou province, Sichuan Province, Yunnan Province, Tibet), Northwest of China (Shanxi province (Xi\'an), Gansu province, Ningxia Hui Autonomous Region, Xinjiang Uyghur autonomous region).

M: model of meta-analysis; R: random-effects model; F: fixed-effects model.*P~H~: p* value of heterogeneity test. *P~E~*:*p v*alue of

Egger\'s test. *P~OR~*: *P*\<0.001 replace the *P* = 0.000 and the *P* less than 0.001. @: *p* values could not be calculated.

NA: not available.

10.1371/journal.pone.0102372.t005

###### Subgroup analysis of the association between *GSTM1-GSTT1* null genotype and lung cancer risk.

![](pone.0102372.t005){#pone-0102372-t005-5}

  Polymorphism                Null vs. Present              No. of studies (cases/controls)      Odds ratio         M     Heterogeneity   *P~E~*          
  --------------- ---------------------------------------- --------------------------------- ------------------- ------- --------------- -------- ------- -------
  *GSTM1-GSTT1*                 All studies                           8(775/1495)             1.29\[1.03,1.63\]   0.028         R          61.7    0.011   0.320
                    subgroup analyses by number of case                                                                                                   
                                   \<100                              5(327/461)              1.33\[1.07,1.65\]   0.009         F          21.6    0.277   0.407
                                    ≥100                              3(448/1034)             1.30\[0.84,2.00\]   0.238         R          82.8    0.003   0.387
                   subgroup analyses by source of control                                                                                                 
                              Population-based                        7(722/1423)             1.34\[1.06,1.71\]   0.016         R          64.5    0.010   0.126
                               Hospital-based                          1(53/72)               0.80\[0.40,1.60\]   0.528         R          <@>      <@>     <@>
                    subgroup analyses by research design                                                                                                  
                           Epidemiological study                      7(698/1418)             1.34\[1.03,1.73\]   0.029         R          66.4    0.007   0.293
                         Non-epidemiological study                     1(77/77)               1.04\[0.66,1.63\]   0.864         R          <@>      <@>     <@>

M: model of meta-analysis; R: random-effects model; F: fixed-effects model.*P~H~*: *p* value of heterogeneity test. *P~E~*: *p* value of Egger\'s test. *P~OR~*: *P*\<0.001 replace the *P* = 0.000 and the *P* less than 0.001. @: *p* values could not be calculated.

3. Cumulative meta-analysis {#s3c}
---------------------------

The cumulative meta-analysis was used to examine the fluctuation of the eligible studies with changes in the publication year or sample size. With the publication year development and sample size increase, the cumulative meta-analysis of *GSTM1* tended to be stable. However, no significant difference in the trend was found in the *GSTT1* and *GSTM1-GSTT1* cumulative meta-analysis. The results for cumulative meta-analysis are shown in [Figure 5](#pone-0102372-g005){ref-type="fig"} and [Figure 6](#pone-0102372-g006){ref-type="fig"}.

![Cumulative meta-analysis of the association between GSTM1 null genotype and lung cancer susceptibility.\
(a) publication time cumulative meta-analysis of GSTM1 variants and lung cancer risk; (b) sample size cumulative meta-analysis of GSTM1 variants and lung cancer risk.](pone.0102372.g005){#pone-0102372-g005}

![Cumulative meta-analysis of the association between *GSTT1*/*GSTM1-GSTT1* genetic polymorphisms and lung cancer susceptibility.\
(a) publication time cumulative meta-analysis of *GSTT1* variants and lung cancer risk; (b) sample size cumulative meta-analysis of *GSTT1* variants and lung cancer risk; (c) publication time cumulative meta-analysis of *GSTM1-GSTT1* variants and lung cancer risk; (d) sample size cumulative meta-analysis of *GSTM1-GSTT1* variants and lung cancer risk.](pone.0102372.g006){#pone-0102372-g006}

4. Subgroup analysis {#s3d}
--------------------

Due to the fact that all studies were middle to high heterogeneities, analyses on nine subgroups as mentioned above were performed accordingly. No significant increase in the risk of lung cancer was detected in either null genotype of *GSTM1* in the northwest, or null genotype of *GSTT1* in the north, southwest or northwest of China ([Table 3](#pone-0102372-t003){ref-type="table"}, [Table 4](#pone-0102372-t004){ref-type="table"}). The excess lung cancer risk was found associated with null *GSTM1* genotype, but not with null *GSTT1* genotype, in both smokers and nonsmokers. Besides, smokers had a higher risk than non-smokers in the association between *GSTM1* null genotype and lung cancer risk. The interaction of *CYP1A1* (Msp1) with mt/mt genotype and *GSTM1* null genotype could enhance the risk of lung cancer, and the OR of which were a little higher than the other two *CYP1A1* (Msp1) genotypes with *GSTM1* null.

However, high heterogeneities in the analysis of the association between *GSTM1* variants and lung cancer were found in the studies from northeast and southwest China. The subgroups of AC and smokers also showed greater heterogeneities (*I^2^*:53.8% and 50.3%, respectively). Meanwhile, the subgroup analyses of *GSTT1* genetic polymorphisms and lung cancer susceptibility demonstrated high heterogeneities in the subgroups of central China, southwest China, and smokers.

When analyzing the five subgroups of case numbers ≥100, population-based controls, epidemiological studies, test material from white blood cells, and quality score (7--8), all pooled results showed significant association between *GSTT1* genetic polymorphisms and lung cancer risk, but high heterogeneities also appeared. However, subgroups of case numbers \<100, hospital-based controls, non-epidemiological studies, test materials from involved tissue or cells or not available, and quality score (4--5), all pooled results showed no significant association between *GSTT1* genetic polymorphisms and lung cancer risk ([Table 4](#pone-0102372-t004){ref-type="table"}).

In the analysis of the relationship of *GSTM1-GSTT1* genetic polymorphisms with lung cancer risk, no significant association was found in the subgroup of case numbers (≥100). Along with significant increase risks in the subgroup of population-based controls and epidemiological studies, high heterogeneity was also found ([Table 5](#pone-0102372-t005){ref-type="table"}).

5. Galbraith plot and sensitivity analysis {#s3e}
------------------------------------------

In [Figure 7a](#pone-0102372-g007){ref-type="fig"}, 7 articles were identified in the Galbraith plot as the outliers [@pone.0102372-Han1], [@pone.0102372-Zheng1], [@pone.0102372-Chan1], [@pone.0102372-Ye2], [@pone.0102372-ChanYeung1], [@pone.0102372-London1], [@pone.0102372-Sun1]. After omitting these records, the adjusted association of *GSTM1* null genetype and lung cancer risk showed a lower heterogeneity and an increased susceptibility (fixed-effects model: OR = 1.23, 95% CI: 1.19 to 1.27, *P*\<0.001). Besides, according to the Galbraith plot of the association of *GSTT1* or *GSTM1-GSTT1* interaction polymorphisms with lung cancer risk, 2 articles [@pone.0102372-Cao1], [@pone.0102372-London1] were obviously spotted as the outliers, which were the possible sources for the heterogeneities. After adjustment, the association of both groups were all increased (fixed-effects model: OR*~GSTT1~* = 1.18, 95% CI: 1.10 to 1.26, *P*\<0.001; OR*~GSTM1-GSTT1~* = 1.33, 95% CI: 1.10 to 1.61, *P* = 0.004) and the *I^2^* indexes were decreased to 29.5% for *GSTT1* and 2.1% for *GSTM1-GSTT1*, respectively ([Figure 7](#pone-0102372-g007){ref-type="fig"}, [Table 6](#pone-0102372-t006){ref-type="table"}). Then, the sensitivity analysis was carried out in each group (data not shown).

![Galbraith plot of association between GSTs polymorphisms and lung cancer risk.\
Each figure represents a unique article in this meta-analysis. The figures outside the three lines were spotted as the outliers and the possible sources of heterogeneity in the analysis pooled from the total available number. (a) Galbraith plot result of GSTM1 polymorphisms and lung cancer risk; (b) Galbraith plot result of GSTT1 polymorphisms and lung cancer risk; (c) Galbraith plot result of GSTM1-GSTT1 dual null genotype and lung cancer risk.](pone.0102372.g007){#pone-0102372-g007}

10.1371/journal.pone.0102372.t006

###### Subgroup analysis of ^\$^the adjusted association between *GSTM1* null genotype, *GSTT1* null genotype and *GSTM1-GSTT1* dual null genotype and lung cancer risk.
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  Polymorphism     Null vs. Present   No. of studies (cases/controls)      Odds ratio          M      Heterogeneity   *P~E~*          
  --------------- ------------------ --------------------------------- ------------------- --------- --------------- -------- ------- -------
  *GSTM1*            All studies               61(7455/8364)            1.23\[1.19,1.27\]   \<0.001         F          2.2     0.427   0.337
  *GSTT1*            All studies               15(1773/2116)            1.18\[1.10,1.26\]   \<0.001         F          29.5    0.135   0.296
  *GSTM1-GSTT1*      All studies                6(439/580)              1.33\[1.10,1.61\]    0.004          F          2.1     0.403   0.349

M: model of meta-analysis; R: random-effects model; F: fixed-effects model.PH: p value of heterogeneity test.PE: p value of Egger\' test. POR: P\<0.001 replace the P = 0.000 and the P less than 0.001. ^\$^: adjusted association (after omitting several articles from Galbraith plot).

6. Potential publication bias {#s3f}
-----------------------------

Begg\'s funnel plots and Egger\'s linear regression test were used to evaluate the potential publication bias ([Figure 8a](#pone-0102372-g008){ref-type="fig"} and [Figure 8b](#pone-0102372-g008){ref-type="fig"} for *GSTM1*; [Figure 8c](#pone-0102372-g008){ref-type="fig"} and [Figure 8d](#pone-0102372-g008){ref-type="fig"} for *GSTT1*; [Figure 8e](#pone-0102372-g008){ref-type="fig"} and [Figure 8f](#pone-0102372-g008){ref-type="fig"} for *GSTM1-GSTT1*). No publication bias was detected by Egger\'s test (*P~E~* = 0.245 for *GSTM1*, *P~E~* = 0.510 for *GSTT1* and *P~E~* = 0.320 for dual-null genotype of *GSTM1-GSTT1*). The Trim and Fill test further confirmed the results (data not shown).

![Begg\'s funnel plot and Egger\'s linear regression test of the association between *GSTs* polymorphisms and lung cancer risk.\
Begg\'s funnel plot is used to detect potential publication bias in which a symmetric funnel shape means no publication bias. Egger\'s linear regression test is used to quantify the potential presence of publication bias; (a) (b) *GSTM1*: No publication bias has been found from 68 inclusive studies about the association between *GSTM1* polymorphisms and lung cancer risk by Begg\'s??? test and Egger\'s test, respectively; (c)(d) *GSTT1*: No publication bias has been found from 17 inclusive studies about the association between *GSTT1* polymorphisms and lung cancer risk by Begg\'s test and Egger\'s test, respectively; (e)(f) *GSTM1-GSTT1* dual-null genotype: No publication bias has been found from 8 inclusive studies about the association between *GSTM1-GSTT1* dual-null genotype and lung cancer risk by Begg\'s test and Egger\'s test, respectively.](pone.0102372.g008){#pone-0102372-g008}

Discussion {#s4}
==========

To our knowledge, this is the first large-scale systematic meta-analysis on the correlation of two vital GSTs genetic polymorphisms with lung cancer risk in the Chinese population over the past decade. Our pooled analysis on the original studies in the Chinese population provided efficient and effective evidences of an increased association between null *GSTM1*, null *GSTT1* or dual null *GSTM1-GSTT1* genotypes and lung cancer risk when omitting some possible heterogeneous records. This large-scale systematic review on sufficient studies helps to reduce random error and increase the statistical power. Simultaneously, by using the same inclusive criteria, it can also ensure the pooled results more precise and exact. It is well known that different populations have different genetic variations and environmental exposure factors. Previous studies paid more attention to the Asian or special environmental population [@pone.0102372-Ye1], [@pone.0102372-Hosgood1]. We only focused on the Chinese ethnicity.

In subgroup analysis of *GSTM1* genetic variants, the northeast and southwest of China were found to be a source of difference, and in subgroup analysis of *GSTT1* genetic variants, the southwest regions of China was also suggested as the major heterogeneous source. Furthermore, no association between GSTs and lung cancer susceptibility was evident in the Chinese population living in the above regions. To our knowledge, the greatest population in the southwest and northwest areas of China is the Chinese ethnic minorities. The complex genetic backgrounds of various ethnic minorities might have an influence on lung cancer susceptibility. In the subgroup of histopathological classification, increased association between the genetic polymorphisms and SC (OR and 95% CI:1.20 \[1.12,1.27\]) and SCLC (OR and 95% CI:1.29\[1.13,1.47\]) risk were found with a low heterogeneity. These results for the first time imply a clue that SCLC could have a stronger association with *GSTM1* deficiency than the other two types while no statistic difference was found among 3 pathological types from available data. Due to the limited number of studies and comparatively diversity among various studies, more well designed epidemiological studies should be performed for various pathological types of lung cancers (especially for pulmonary AC). Additionally, we found that there was increased susceptibility between *GSTM1* null genotype and lung carcinoma risk in different phase I isoenzymes of *CYP1A1*. These results not only further confirm our conclusion, but also imply some enlightenments. For instance, under a higher OR with no heterogeneity, people with *CYP1A1* (mt/mt) and *GSTM1* null genotype should pay more attention to avoiding exposure to harmful environmental factors associated with lung cancer. Naturally, more studies including a genome-wide association study (GWAS) are necessary to prove this hypothesis. Due to the limited number of studies, the same analysis for the *GSTT1* null genotype was not performed.

The subgroup analyses of the smoking status for *GSTM1* studies further suggested that the possible risk factor of GSTM1 null genotype is different. However, eligible studies for G*STT1* failed to reach a significant association, which might be caused by a limited number of studies with high heterogeneities. Unclear smoking definition and inconsistent classification of the amount of tobacco consumed among different studies might all have an influence on the stability, reliability, as well as further in-depth analyses of the results. Therefore, clear smoking definition and consistent classification for the smoking status are necessary in any future research.

In the sensitivity analyses and Galbraith plot, 7 heterogeneous articles for *GSTM1* were detected by the Galbraith plot. The potential bias of these articles might be the result of small sample size, complex population composition, distinction of testing materials [@pone.0102372-Chan1], and/or unknown reasons [@pone.0102372-London1]. After omitting these articles, no heterogeneity was detected. Additionally, the Galbraith plot for the *GSTT1* and *GSTM1-GSTT1* groups spotted two of the same articles [@pone.0102372-Cao1], [@pone.0102372-London1] as the major source of between-heterogeneity. After removing these two articles, heterogeneity decreased substantially. Compared to the raw OR and 95% CI, the adjusted OR and 95% CI of *GSTT1* and *GSTM1-GSTT1* were both increased.

Cumulative meta-analysis showed a comparable change in the trend in the accumulated OR and 95% CI for *GSTT1* or *GSTM1-GSTT1* with the publication time development and sample size increase. Thus, to identify the real association between the *GSTT1* null type, *GSTM1-GSTT1* dual null type and lung cancer susceptibility, more large-scale case-control and cohort studies from multi-centers should be performed. At last, no publication biases were detected in our meta-analysis.

It\'s worth mentioning that Hardy-Weinberg equilibrium has been widely recommended in testing studies of genetic polymorphisms and diseases, the violations of which may have potential impacts on the results [@pone.0102372-Trikalinos1]. In this paper, no individual studies made any distinction between heterozygotes or homozygotes and *GSTM1* and *GSTT1* in the present genotype, so Hardy-Weinberg equilibrium tests could not be performed. Therefore, the Hardy-Weinberg equilibrium test results reported in some of the 71 articles might not be reliable.

It is worthy to note that several other limitations might be included in this study: (1) as common observational studies, case-control studies were susceptible to various biases (including recall bias of smoking status, different diagnostic criteria and the investigation bias of NOS score). These biases could influence the final findings of this study; (2) conclusions of this study were partly based on literatures obtained from the hospital-based population, which might not represent the whole population; (3) eligible studies for this study covered nearly all regions in China, but the article number was still insufficient in some less developed or relatively sparsely regions; (4) the interaction of genes with environmental factors, especially with special external occupational exposure and environmental pollution, might all contribute to the development of lung cancer. Factors above might also contribute to a possible source of heterogeneity of our results. Owning to the limitation of the data, this paper did not analyze the interaction effects of these factors; (5) absence of HWE test in the control group, some unbalance controls could lead to some bias in the final results.

Taken together, after a decade of extensive studying on this topic, our findings suggest that *GSTM1* and *GSTT1* genetic polymorphisms are associated with increased lung cancer risk in the Chinese population. Because of multifactor etiology of the interaction of gene-gene and gene-environment in the development of lung cancer, large-scale and methodologically sound studies with different environmental background and other genetic polymorphisms should be carried out to explore the real association between GSTs variants and various pathological types of lung cancer.
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